Literature DB >> 19112098

Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transport.

Jason R Waggoner1, Kenneth S Ginsburg, Bryan Mitton, Kobra Haghighi, Jeffrey Robbins, Donald M Bers, Evangelia G Kranias.   

Abstract

Phospholamban has been suggested to be a key regulator of cardiac sarcoplasmic reticulum (SR) Ca cycling and contractility and a potential therapeutic target in restoring the depressed Ca cycling in failing hearts. Our understanding of the function of phospholamban stems primarily from studies in genetically altered mouse models. To evaluate the significance of this protein in larger mammalian species, which exhibit Ca cycling properties similar to humans, we overexpressed phospholamban in adult rabbit cardiomyocytes. Adenoviral-mediated gene transfer, at high multiplicities of infection, resulted in an insignificant 1.22-fold overexpression of phospholamban. There were no effects on twitch Ca-transient amplitude or decay under basal or isoproterenol-stimulated conditions. Furthermore, the SR Ca load and Na/Ca exchanger function were not altered. These apparent differences between phospholamban overexpression in rabbit compared with previous findings in the mouse may be due to a significantly higher (1.5-fold) endogenous phospholamban-to-sarco(endo)plasmic reticulum Ca-ATPase (SERCA) 2a ratio and potential functional saturation of SERCA2a by phospholamban in rabbit cardiomyocytes. The findings suggest that important species-dependent differences in phospholamban regulation of SERCA2a occur. In larger mammals, a higher fraction of SERCA2a pumps are regulated by phospholamban, and this may influence therapeutic strategies to enhance cardiac contractility and functional cardiac reserve.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19112098      PMCID: PMC2660221          DOI: 10.1152/ajpheart.00272.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  29 in total

Review 1.  Phospholamban and cardiac contractile function.

Authors:  A G Brittsan; E G Kranias
Journal:  J Mol Cell Cardiol       Date:  2000-12       Impact factor: 5.000

2.  Phospholamban-to-SERCA2 ratio controls the force-frequency relationship.

Authors:  M Meyer; W F Bluhm; H He; S R Post; F J Giordano; W Y Lew; W H Dillmann
Journal:  Am J Physiol       Date:  1999-03

3.  Functional alterations in adult rat myocytes after overexpression of phospholamban with use of adenovirus.

Authors:  K Davia; R J Hajjar; C M Terracciano; N S Kent; H K Ranu; P O'Gara; A Rosenzweig; S E Harding
Journal:  Physiol Genomics       Date:  1999-08-31       Impact factor: 3.107

Review 4.  Phospholamban: protein structure, mechanism of action, and role in cardiac function.

Authors:  H K Simmerman; L R Jones
Journal:  Physiol Rev       Date:  1998-10       Impact factor: 37.312

5.  Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function.

Authors:  Mark T Ziolo; Jody L Martin; Julie Bossuyt; Donald M Bers; Steven M Pogwizd
Journal:  Circ Res       Date:  2005-03-24       Impact factor: 17.367

6.  Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation.

Authors:  R H Schwinger; G Münch; B Bölck; P Karczewski; E G Krause; E Erdmann
Journal:  J Mol Cell Cardiol       Date:  1999-03       Impact factor: 5.000

7.  Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.

Authors:  S Minamisawa; M Hoshijima; G Chu; C A Ward; K Frank; Y Gu; M E Martone; Y Wang; J Ross; E G Kranias; W R Giles; K R Chien
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

Review 8.  Abnormalities of calcium cycling in the hypertrophied and failing heart.

Authors:  S R Houser; V Piacentino; J Weisser
Journal:  J Mol Cell Cardiol       Date:  2000-09       Impact factor: 5.000

9.  Maximal inhibition of SERCA2 Ca(2+) affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban.

Authors:  A G Brittsan; A N Carr; A G Schmidt; E G Kranias
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

10.  Phospholamban overexpression in transgenic rabbits.

Authors:  James Scott Pattison; Jason R Waggoner; Jeanne James; Lisa Martin; James Gulick; Hanna Osinska; Raisa Klevitsky; Evangelia G Kranias; Jeffrey Robbins
Journal:  Transgenic Res       Date:  2007-09-19       Impact factor: 2.788

View more
  5 in total

1.  Effects of increased systolic Ca²⁺ and phospholamban phosphorylation during β-adrenergic stimulation on Ca²⁺ transient kinetics in cardiac myocytes.

Authors:  Steve R Roof; Thomas R Shannon; Paul M L Janssen; Mark T Ziolo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-15       Impact factor: 4.733

2.  L30A Mutation of Phospholemman Mimics Effects of Cardiac Glycosides in Isolated Cardiomyocytes.

Authors:  Ryan D Himes; Nikolai Smolin; Andreas Kukol; Julie Bossuyt; Donald M Bers; Seth L Robia
Journal:  Biochemistry       Date:  2016-10-25       Impact factor: 3.162

Review 3.  Na/K-ATPase--an integral player in the adrenergic fight-or-flight response.

Authors:  Donald M Bers; Sanda Despa
Journal:  Trends Cardiovasc Med       Date:  2009-05       Impact factor: 6.677

4.  Excitation-contraction coupling changes during postnatal cardiac development.

Authors:  Andrew P Ziman; Norma Leticia Gómez-Viquez; Robert J Bloch; W J Lederer
Journal:  J Mol Cell Cardiol       Date:  2009-10-08       Impact factor: 5.000

5.  Myocardial contractility is preserved early but reduced late after ovariectomy in young female rats.

Authors:  Altemar S Paigel; Rogerio F Ribeiro; Aurelia A Fernandes; Gabriel P Targueta; Dalton V Vassallo; Ivanita Stefanon
Journal:  Reprod Biol Endocrinol       Date:  2011-04-23       Impact factor: 5.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.